Registry Study of Genesys HTA for Treatment of Menorrhagia

NCT ID: NCT01197547

Last Updated: 2021-03-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1014 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-11-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a clinical registry of an FDA approved device system called the Genesys Hydro ThermAblatorTM (HTA) system (Boston Scientific). The HTA system's intended use is to be inserted, by a trained physician, into the uterus, where it will fill and circulate fluid that is warm enough to change the characteristics of the uterine lining. This is done with the anticipated result of improving menstrual bleeding symptoms.

The purpose of this FDA-mandated registry is to obtain clinical experience on the use the Genesys HTA™ system, under normal clinical conditions, and document its safety and technical reliability.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menorrhagia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Genesys HTA

Genesys HTA Endometrial Ablation

Group Type OTHER

Genesys HTA

Intervention Type DEVICE

Genesys HTA Endometrial Ablation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genesys HTA

Genesys HTA Endometrial Ablation

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Genesys HTA Endometrial Ablation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject must meet the approved indication for use to be considered for this registry.

Exclusion Criteria

* All subjects contraindicated for the treatment of the Genesys HTA System per the Directions for Use will be excluded:

1. The subject is pregnant or wants to be pregnant in the future
2. The subject has known or suspected endometrial carcinoma or premalignant change of the endometrium, such as adenomatous hyperplasia
3. The subject has active pelvic inflammatory disease or pyosalpinx
4. The subject has hydrosalpinx
5. The subject in whom a tight cervical seal cannot be established and maintained around the procedure sheath
6. The subject has an anatomical condition (e.g. history of previous classical cesarean section or transmural myomectomy) or pathologic condition (e.g. long term medical therapy) that could lead to weakening of the myometrium
7. The subject has an intrauterine device in place
8. The subject has an active genital or urinary tract infection (e.g. cervicitis, endometritis, vaginitis, cystitis, etc.) at the time of treatment
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Minerva Surgical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Bowman, M.D.

Role: STUDY_DIRECTOR

Boston Scientific Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sharp Mary Birch

San Diego, California, United States

Site Status

Christiana Hospital

Newark, Delaware, United States

Site Status

Shelnutt Obstetrics and Gynecology

Athens, Georgia, United States

Site Status

Health South Surgecenter of Louisville

Louisville, Kentucky, United States

Site Status

Wayne State University Physician Group

Southfield, Michigan, United States

Site Status

Seven Hills OB GYN Associates

Cincinnati, Ohio, United States

Site Status

Complete Healthcare for Women

Columbus, Ohio, United States

Site Status

Associates in Women's Healthcare

Philadelphia, Pennsylvania, United States

Site Status

Schuykill Medical Center South

Pottsville, Pennsylvania, United States

Site Status

Chattanooga Medical Research

Chattanooga, Tennessee, United States

Site Status

State of Franklin Healthcare Associates

Johnson City, Tennessee, United States

Site Status

Associates in Obstetrics and Gynecology

Bedford, Texas, United States

Site Status

Central Womens Care PA

Dallas, Texas, United States

Site Status

Doreen Moser, DO

Grapevine, Texas, United States

Site Status

MacArthur OBGYN

Irving, Texas, United States

Site Status

Personalized Women's Healthcare

Plano, Texas, United States

Site Status

Ogden Clinic

Ogden, Utah, United States

Site Status

Old Farm Obstetrics and Gynecology

Salt Lake City, Utah, United States

Site Status

Milwaukee ObGyn

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U8088

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Kinesiotape on Emesis in Pregnant Women
NCT06625632 NOT_YET_RECRUITING NA
Hyaluronic Acid and Uterine Synechiae
NCT02248376 COMPLETED PHASE3